announces

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent…

2 days ago

The Ferrero Group announces new governance and leadership roles, reporting into Giovanni Ferrero, President of Ferrero International S.A.

Alessandro Nervegna will be appointed as new Chief Executive Officer of Ferrero Core, driving growth of the Group's core categories.…

2 days ago

Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing

Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced…

3 days ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…

3 days ago

3iQ Announces Successful Closing of Previously Announced Transaction with Coincheck Group N.V.

TORONTO, March 2, 2026 /PRNewswire/ -- 3iQ Corp. ("3iQ"), a global pioneer in institutional digital asset investment solutions, is pleased…

3 days ago

Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today…

4 days ago

Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 4.474 Million Tokens, and Total Crypto and Total Cash Holdings of $9.9 Billion

Bitmine has 3,040,483 staked ETH, representing $6.0 billion at $1,976 per ETH; MAVAN staking solution on track to launch Q1…

4 days ago

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and…

4 days ago

Medit Announces “Glow Together” International Women’s Day Campaign

SEOUL, South Korea, Feb. 27, 2026 /PRNewswire/ -- Medit, a global provider of digital dentistry solutions, today announced that the…

6 days ago

SEALSQ Expands Japanese Footprint and Announces Key Local Event Participations in March to Showcase PQC Leadership, Aligning with Japan Government’s 2035 Quantum Security Mandate

February 27, 2026 09:15 ET  | Source: SEALSQ Geneva, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES)…

7 days ago